Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06081452
Other study ID # 6634264
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 17, 2023
Est. completion date December 17, 2024

Study information

Verified date October 2023
Source Imperial College London
Contact Pallavi Huma Arya
Phone 02075948197
Email h.arya@imperial.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A brief survey for the public to determine interest in health surveillance and disease detection


Description:

There are numerous barriers and favourable conditions that affect the acceptability of a screening test for cancer. Such factors have been investigated in the context of some of the current screening programs. Through this survey the investigators want to increase researcher awareness of these factors with the hope that this information will aid policy makers and guide future research. There has been widening public interest in general health-surveillance in addition to disease detection. Breath testing has the potential to be a one-for-all non-invasive test to detect health domains. Through this survey, the investigators wish to understand public opinions about breath testing for health. This survey consists of questions aiming to gather views on non-invasive testing for health and disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 17, 2024
Est. primary completion date June 17, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Member of the public above the age of 18 Exclusion Criteria: - Member of the public below the age of 18

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Survey
Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.

Locations

Country Name City State
United Kingdom Imperial College London London

Sponsors (1)

Lead Sponsor Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of breath testing Proportion of people that find breath testing an acceptable means to determine health or disease 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients